RhumbLine Advisers’s Maravai LifeSciences MRVI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $471K | Buy |
195,272
+32,940
| +20% | +$79.4K | ﹤0.01% | 2714 |
|
|
2025
Q1 | $359K | Sell |
162,332
-22,889
| -12% | -$50.6K | ﹤0.01% | 2789 |
|
|
2024
Q4 | $1.01M | Buy |
185,221
+16,712
| +10% | +$91.1K | ﹤0.01% | 2242 |
|
|
2024
Q3 | $1.4M | Sell |
168,509
-2,980
| -2% | -$24.8K | ﹤0.01% | 2091 |
|
|
2024
Q2 | $1.23M | Buy |
171,489
+39,955
| +30% | +$286K | ﹤0.01% | 2136 |
|
|
2024
Q1 | $1.14M | Sell |
131,534
-14,722
| -10% | -$128K | ﹤0.01% | 2184 |
|
|
2023
Q4 | $958K | Buy |
146,256
+9,329
| +7% | +$61.1K | ﹤0.01% | 2275 |
|
|
2023
Q3 | $1.37M | Sell |
136,927
-22,310
| -14% | -$223K | ﹤0.01% | 2039 |
|
|
2023
Q2 | $1.98M | Buy |
159,237
+28,543
| +22% | +$355K | ﹤0.01% | 1907 |
|
|
2023
Q1 | $1.83M | Buy |
130,694
+12,463
| +11% | +$175K | ﹤0.01% | 1848 |
|
|
2022
Q4 | $1.69M | Buy |
118,231
+6,749
| +6% | +$96.6K | ﹤0.01% | 1869 |
|
|
2022
Q3 | $2.85M | Buy |
111,482
+5,581
| +5% | +$142K | ﹤0.01% | 1572 |
|
|
2022
Q2 | $3.01M | Buy |
105,901
+12,165
| +13% | +$346K | ﹤0.01% | 1538 |
|
|
2022
Q1 | $3.31M | Sell |
93,736
-2,692
| -3% | -$94.9K | ﹤0.01% | 1558 |
|
|
2021
Q4 | $4.04M | Buy |
96,428
+11,577
| +14% | +$485K | 0.01% | 1488 |
|
|
2021
Q3 | $4.16M | Buy |
84,851
+17,298
| +26% | +$849K | 0.01% | 1458 |
|
|
2021
Q2 | $2.82M | Buy |
67,553
+3,690
| +6% | +$154K | ﹤0.01% | 1774 |
|
|
2021
Q1 | $2.28M | Buy |
+63,863
| New | +$2.28M | ﹤0.01% | 1855 |
|